This national, multicenter, open-label phase 2 study without any control arm aims to evaluate
the activity of cetuximab monotherapy in the treatment of refractory colorectal cancer in
subjects with K-RAS mutated and FcγRIIa polymorphism tumors, in which there is no therapeutic
alternative for treatment. Failure of the first and second line conventional therapeutic
lines was documented.